ORYOryzon GenomicsORY info
$2.08info-1.37%24h
Global rank19998
Market cap$125.54M
Change 7d5.17%
YTD Performance-3.11%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Oryzon Genomics (ORY) Stock Overview

    Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

    ORY Stock Information

    Symbol
    ORY
    Address
    Sant Ferran 74Cornellà de Llobregat, 08940Spain
    Founded
    -
    Trading hours
    -
    Website
    https://www.oryzon.com
    Country
    🇪🇸 Spain
    Phone Number
    34 93 515 13 13

    Oryzon Genomics (ORY) Price Chart

    -
    Value:-

    Oryzon Genomics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.08
    N/A
    Market Cap
    $125.54M
    N/A
    Shares Outstanding
    60.34M
    N/A
    Employees
    43.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org